Abstract

STABILITY INDICATING ECO GREEN RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF DAPAGLIFLOZIN PROPENDIOL MONOHYDRATE AND TENELIGLIPTIN IN TABLETS DOSAGE FORM

Isha N. Thummar*, Khyati P. Bhupta, Dhirendra Kumar Tarai and Santosh R. Kirtane

.

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, posing a significant global health burden. Effective management often requires a combination of pharmacological agents targeting different pathophysiological pathways. Dapagliflozin, an SGLT2 inhibitor, lowers blood glucose by promoting renal glucose excretion independently of insulin, while Teneligliptin, a DPP-4 inhibitor, enhances glucose-dependent insulin secretion through incretin hormone modulation. Both agents offer additional benefits including weight reduction, cardiovascular protection, and low risk of hypoglycemia. When used together, Dapagliflozin and Teneligliptin provide a synergistic effect, improving glycemic control and reducing complications associated with T2DM. This combination represents a promising therapeutic strategy in the modern management of Type 2 diabetes.

Keywords: Type 2 diabetes mellitus (T2DM); Dapagliflozin; Teneligliptin; SGLT2 inhibitors; DPP-4 inhibitors; combination therapy; glycemic control; incretin hormones; cardiovascular benefits; insulin resistance.